You are here

Article info

Article menu

Download PDFPDF

Commentary
Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

Authors

  1. ↵a mike.wong{at}med.usc.edu
  2. ↵b howard.kaufman{at}rutgers.edi
  3. ↵c gdaniels{at}ucsd.edu
  4. ↵d dmcdermo{at}bidmc.harvard.edu
  5. ↵e sandra.aung{at}prometheuslabs.com
  6. ↵f jlowder{at}prometheuslabs.com
  7. ↵g Michael.morse{at}duke.edu
View Full Text

Citation

Wong MK, Kaufman HL, Daniels GA, et al
Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
Journal for ImmunoTherapy of Cancer 2014;2:20. doi: 10.1186/2051-1426-2-20

Publication history

  • Received March 28, 2014
  • Accepted April 23, 2014
  • First published June 18, 2014.
Online issue publication 
February 09, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.